Oral mucositis is common, painful, dose-limiting toxicity of drug and radiation therapy for cancer. In granulocytopenic patients, the ulcerations which accompany mucositis are frequent portals of entry for indigenous oral bacteria often leading to bacteremias or sepsis. The complexity of mucositis as a biological process has only recently been appreciated. The condition appears to represent a sequential interaction of the oral mucosal cells and tissues, pro-inflammatory cytokines, and local environmental factors in the mouth such as microorganisms and saliva. The recognition that the pathophysiology of mucositis is a multifactorial process has presented opportunities for intervention based on biological attenuation. Interleukin-11, a pleotropic cytokine, has a range of activities which is potentially relevant to mucositis. Consequently, it has been used successfully to modify the development, severity and course of mucositis in an animal model which closely mimics the equivalent human condition.
Introduction
Destruction of the oral mucosa as a consequence of myeloablative cancer chemotherapy results in full thickness epithelial ulceration with consequent pain and loss of function. Mucositis is common and occurs to some degree in more than onethird of all patients receiving anti-neoplastic drug therapy. 1 The frequency and severity are significantly greater among patients who are treated with induction therapy for leukemia or with many of the conditioning regimens for bone marrow transplant. Among these individuals, moderate to severe mucositis is not unusual in more than three-quarters of patients. In addition to severe pain, which routinely necessitates parenteral analgesic therapy, and loss of function of such severity as to require total parenteral nutrition, the areas of ulceration become sites of secondary infection. The absence of an intact mucosal barrier provides a ready portal of entry for oral microorganisms to such a degree that the mouth is a frequently identifiable site of origin for bacteremias and sepsis among granulocytopenic cancer patients. 2 With the availability of cytokine therapy to manage hematologic toxicities, mucositis has become one of the most significant dose-limiting toxicities associated with cancer chemotherapy. Furthermore, the impact of mucositis on length of hospital stay, admissions for fluid support or treatment of infection, and its causality as a reason to alter optimum antineoplastic treatment have significant economic consequences. For example, the presence of moderate to severe mucositis among autologous bone marrow transplant recipients being treated for hematologic malignancies resulted in a hospital stay which was 5 days longer than for patients without the condition. 3 Despite its clinical significance, there is currently no therapy to prevent or treat mucositis predictably. A broad range of approaches and agents has been used in an attempt to modify the course of mucositis. These have included compounds that are strictly palliative, others which attempt to protect or modify tissue response to stomatotoxic insult and finally those for which alteration in the mouth's microbial load is targeted.
Results from many studies have often been erratic and not replicable.
A wide variety of topical palliative agents has been used to treat mucositis. The most traditional is probably saline 0.9% which has proven to be more effective than sodium hydroxide. 4 Some reports suggest that cryotherapy using ice chips is of some benefit in reducing chemotherapy-induced stomatotoxicity. 5, 6 Sucralfate, an ulcer-coating polysaccharide, when used to treat radiation-induced mucositis in double-blind randomized trials, failed to provide a statistically significant benefit compared to controls. 7, 8 Topical lidocaine and dyclonine HCl provide transient local pain control, but are generally not sufficient for severe mucositis in which parenteral pain medications are indicated.
Both GM-CSF and G-CSF have been proposed as interventions for mucositis. Of the two, GM-CSF has been the more extensively studied. While the results of a number of unblinded, non-randomized pilot studies suggested that GM-CSF might be beneficial for treatment of mucositis, 9,10 the results of a randomized, double-blind, dose-ranging study in which the cytokine was administered topically failed to demonstrate efficacy. 11 In an attempt to protect proliferating mucosal basal cells, TGF-␤3 was administered prior to chemotherapy (5-FU) in an animal model and proved to successfully attenuate the course of mucositis. 12 Both EGF 13 and KGF 14 might have roles in effecting epithelial susceptibility to stomatotoxic therapy or in promoting healing following tissue damage.
Still another approach has been to use compounds which are thought to be cytoprotective of normal cells. Among these agents, amifostine, 15 vitamins with antioxidant properties, 16 and prostaglandins or prostaglandin analogs have been evaluated with mixed results. 17, 18 Pilot studies of two anticholinergic agents, pilocarpine and probanthine, suggest possible benefit, 19, 20 possibly through stimulation of the salivary flow. Direct manipulation of the superficial mucosa by helium-neon laser treatment has also been reported to favorably effect the course of mucositis. 21 Finally, anti-inflammatory agents seemingly are of equivocal benefit. 22 The oral cavity is rich in microorganisms which are thought to negatively affect the course of mucositis. Consequently, there has been a great deal of interest in evaluating the potential of local antimicrobial therapy on the course of stomatotoxicity. In general, the results of randomized, blinded trials with such intervention have been variable. Results of studies using single agent therapy in the form of chlorhexidine gluconate, 23, 24 or multiagent trouches, 25, 26 have been inconsistent, although there appear to be trends suggesting that a reduction in oral bacterial load favorably influences the course of mucositis. 27, 28 In reviewing attempts at mucositis intervention it seems clear that the rationale for therapy has been based on a number of assumptions with respect to the development and physiologic course of the condition, rather than on a sound understanding of its biological basis. Furthermore, the wide variability of results of clinical trials suggests a complexity which has generally not been fully appreciated. Consequently, within the past few years, the need to define mucositis as a pathologic process has been recognized.
Mucositis as a pathologic process
Historically, mucositis was viewed as the result of nonspecific toxicity of chemotherapy or radiation therapy directed against the rapidly dividing cells of the oral-basal epithelium. It was believed that drug or radiation exposure resulted in damage to the proliferating cells causing them to cease replication that resulted in atrophy which eventually led to ulcer formation. Clinical and experimental observations supported this hypothesis: patients in whom epithelial proliferation was expected to be rapid (youngsters) developed mucositis more frequently than did elderly patients in whom the rate of proliferation was slower; 29 second, exposure of animals to epidermal growth factor, a cytokine which increased the rate of proliferation, prior to chemotherapy resulted in increased rates of mucositis; 13 third, temporarily protecting the epithelium by inhibiting proliferation just before chemotherapy with TGF-␤3 reduced experimental mucositis. 12 However, a number of clinical observations suggested that the mechanism of injury was more complex than just involving the epithelium. In particular, the results of the effects of agents with little or no reported epithelial activity contradicted a sole epithelial mechanism.
We recently hypothesized that mucositis represents a clinical outcome due to a complex interaction of local tissue (connective tissue, endothelium, epithelium) toxicity, the level of myelosuppression and the oral environment. 30 The local tissue components include an oral mucosa of rapidly renewing stratified squamous epithelium overlying a loose and richly vascular connective tissue base and appear to be responsive to changes in patients' bone marrow status and, particularly, the degree of granulocytopenia. The oral microbial flora, saliva and functional trauma provide an indigenous environment which impacts on the frequency, severity and course of chemotherapy-associated stomatotoxicity.
It is quite likely that the initial oral tissue response to chemotherapy and radiation occurs at the endothelial and connective tissue level. We believe that free radical formation leads to the disruption of fibronectin with subsequent activation of transcription factors, stimulation of pro-inflammatory cytokine production and tissue damage. A relationship between the presence of tumor necrosis factor-alpha (TNF-␣) and IL-1 in serum correlates with the presence of non-hematologic toxicities. 31 It is also likely that injury to endothelial cells occurs simultaneously. 32 Concurrently, damage to the basal epithelial cells prevents their replication. It is unclear whether many of these cells undergo apoptosis or necrosis; the unaffected portion to determine the rate of recovery. An influx of inflammatory cells expressing pro-inflammatory cytokines occurs during the breakdown of the mucosa and peaks just prior to the acme of mucositis. 33 Bacterial colonization of the damaged epithelium occurs and is accelerated by the patient's myelosuppressed state. Typically the nadir follows a day or so after peak mucositis. Bacterial cell wall products from both gram-positive and gram-negative organisms likely then penetrate the injured mucosa and further stimulate the release of damaging cytokines. 34 Finally, the mucosa recovers, a process which takes about 3 weeks in the absence of secondary infection.
Opportunities for intervention
The biologic complexity of mucositis may help to explain the variability of responses which have been observed among patients. Perhaps more importantly it provides a series of opportunities for biologically-based intervention. Illustrative of this have been the results of studies performed with interleukin-11 (IL-11). IL-11 is a multifunctional cytokine with hematopoietic, epithelial and anti-inflammatory activities of possible relevance to mucositis. The naturally occurring mature protein has 178 amino acids with a molecular mass of 19 kDa and is expressed by a wide range of mesenchymal tissues. Recombinant human IL-11 (rhIL-11) has multiple activities identified by in vitro and in vivo studies which may effect mucositis. These activities include stimulation of myeloid progenitor cells, 35 inhibition of proliferation of gastrointestinal epithelial cells, 36 protection of connective tissues secondary to modulation of extracellular matrix metabolism, 37 reduction of pro-inflammatory cytokine expression, 38 and inhibition of apoptosis induction. 39 The modulation of chemotherapy-induced mucositis by rhIL-11 has been studied using a hamster model which mimics the condition in humans. 40 The hamster evolved as the animal of choice for a clinically relevant mucositis model for five reasons: first, the cheek pouch provides an anatomic site which is easily accessible and has a large mucosal surface area; second, the cheek pouch has been well-studied, especially with respect to experimental carcinogenesis; third, the cheek pouch resembles similar human tissue; fourth, the oral bacterial flora of the hamster is remarkably similar to that of humans; and fifth, the size of hamster peripheral blood cells is like humans which makes automated analysis simple and inexpensive. Earlier studies demonstrated that the hamster mucosa and bone marrow were dose-responsive to chemotherapy and that the kinetics of both myelosuppression and mucositis paralleled that described for humans. 41 Additionally, we confirmed the biological activity of rhIL-11 in hamsters by demonstrating thrombopoiesis in response to cytokine administration. 42 Subcutaneous administration of rhIL-11 effectively attenuated mucositis induced by 5-fluoruracil. 42 Twice daily injections of rhIL-11 started on the first day of chemotherapy and continued for 14 days had a favorable impact on oral mucositis, weight loss and survival. The response was dose-dependent. Mucositis development, overall frequency and severity were significantly less in animals treated with therapeutic doses of rhIL-11 compared to low-dose or placebo-treated hamsters. Survival in rhIL-11-treated animals was significantly better than controls.
That the favorable effects of rhIL-11 on mucositis were due to factors unrelated to its myeloproliferative activities was sug-gested by three observations. First, whereas maximum thrombopoiesis was noted 12 days after the initiation of rhIL-11 administration, mucositis suppression was seen by day 7. Second, the favorable effect of rhIL-11 on weight loss preceded increases in peripheral platelet numbers. Finally, direct observation of bone marrow cellularity failed to reveal differences between rhIL-11 and placebo-treated animals, although peripheral white blood cell numbers were higher in hamsters which had received rhIL-11.
Studies are currently underway to fully understand the mechanism(s) by which rhIL-11 modulates chemotherapyinduced mucositis. However, it seems likely that its beneficial effects are a result of the cytokine's ability to modulate a variety of cellular responses within the various tissue compartments which make up the oral mucosa. The ability of rhIL-11 to attenuate the course of mucositis is illustrative of the potential efficacy of biological therapy as a means to prevent and treat this important toxicity.
